Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -994.1%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $7M | — | — | — | — | — |
| Enterprise Value | $5M | $10M | — | — | — | — | — |
| P/E Ratio → | -0.06 | — | — | — | — | — | — |
| P/S Ratio | 0.67 | 1.02 | — | — | — | — | — |
| P/B Ratio | 6.67 | 16.44 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.51 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 22.9% | 22.9% | 36.8% | 19.9% | 14.4% | 29.8% | 33.7% |
| Operating Margin | -176.5% | -176.5% | -17.1% | -4.9% | -1.3% | -37.6% | -64.2% |
| Net Profit Margin | -688.8% | -688.8% | -0.5% | -9.4% | -2.6% | 6.5% | -139.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -994.1% | -994.1% | -14.2% | — | -8.3% | 20.1% | — |
| ROA | -371.9% | -371.9% | -0.4% | -22.4% | -4.4% | 4.6% | -115.8% |
| ROIC | -31.8% | -31.8% | -10.9% | -18.1% | -3.1% | -64.6% | — |
| ROCE | -170.7% | -170.7% | -155.8% | -98.8% | -2.8% | -51.8% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 10.99 | 10.99 | 5.24 | — | 19.25 | 0.18 | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 7.77 | -0.07 | — | 17.46 | -0.32 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | 23.68 | 5.17 | — | — |
| Interest Coverage | -18.36 | -18.36 | 0.66 | -4.26 | -1.55 | 2.06 | -5.42 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.29 | 2.29 | 2.10 | 0.38 | 0.67 | 5.98 | 0.32 |
| Quick Ratio | 1.71 | 1.71 | 1.63 | 0.30 | 0.49 | 5.27 | 0.23 |
| Cash Ratio | 0.37 | 0.37 | 0.43 | 0.03 | 0.08 | 3.94 | 0.07 |
| Asset Turnover | — | 0.78 | 2.21 | 1.84 | 2.66 | 0.59 | 0.83 |
| Inventory Turnover | 2.42 | 2.42 | 6.56 | 16.67 | 19.75 | 6.16 | 5.80 |
| Days Sales Outstanding | — | 220.37 | 80.79 | 21.66 | 13.32 | 53.89 | 39.69 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 3.1% | 2.0% | — | — | — | — | — |
| Total Shareholder Yield | 3.1% | 2.0% | — | — | — | — | — |
| Shares Outstanding | — | $21M | $2M | $12M | $704183 | $497785 | $185925 |
Imminent liquidity and solvency crisis
According to recent financial data, SRXH trades at a price-to-sales ratio of 0.67, which, when viewed alongside a negative trailing P/E of -0.06, suggests that the market has largely abandoned growth expectations in favor of pricing the company as a distressed asset with significant terminal risk.
The lack of a forward P/E or meaningful EV/EBITDA multiple indicates that the market currently views the company's earnings power as non-existent or too volatile to forecast. Investors should monitor whether the current P/S multiple is a floor or if further revenue erosion will necessitate a downward re-rating of the entire enterprise value.
Based on reported figures, SRXH's ROIC has plummeted to -8.6% in 2026Q2, illustrating a consistent failure to generate returns above the cost of capital and suggesting that the firm's investments in clinical infrastructure are currently destroying rather than creating shareholder value.
The persistent negative ROIC trend over the last ten quarters implies that the company's core business model is fundamentally unable to cover its invested capital base. This decay warrants further investigation into whether the company's asset base is impaired or if the current service-delivery model is structurally incapable of achieving profitability.
As reported in quarterly filings, the cash conversion cycle has fluctuated wildly, reaching 134 days in 2026Q2, which suggests that the company is struggling to manage its receivables and inventory effectively compared to its historical performance and industry standards for specialty pharmacy services.
The high DSO of 108 days indicates significant friction in collecting payments from provincial healthcare payers or pharmaceutical partners, which directly pressures the company's limited liquidity. This inefficiency appears to be a structural drag on the business, as the company is forced to finance its operations for longer periods than its peers.
Based on the most recent balance sheet, the current ratio of 1.72 masks a precarious cash position of only $1.3M, which, when compared to the company's high operating burn rate, suggests that the firm may face an imminent liquidity crisis without external capital intervention.
The reliance on inventory and receivables to maintain the current ratio is concerning given the volatility in the company's cash conversion cycle. Investors should monitor the company's ability to meet short-term obligations, as the current liquidity profile appears inadequate to sustain the business through a prolonged period of negative operating cash flow.
The most commonly misapplied metric for SRXH is the price-to-sales ratio, which obscures the company's underlying service-fee model by failing to account for the potential shift from gross to net revenue recognition in its specialty pharmacy contracts.
Using P/S to value this business is misleading because it ignores the high cost of goods sold associated with specialty drugs, which can artificially inflate revenue figures while providing little insight into actual service margins. Analysts should instead focus on gross profit or service-fee revenue to better understand the true earning potential of the company's patient support programs.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SRXH stock.
SRx Health Solutions Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
SRx Health Solutions Inc.'s return on equity (ROE) is -994.1%. The historical average is -0.8%.
Based on historical data, SRx Health Solutions Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
SRx Health Solutions Inc. has 22.9% gross margin and -176.5% operating margin.